Omeros Corporation entered into agreements to repurchase up to $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 for a total purchase price of up to $34.0 million. The repurchases are expected to close between July 6, 2026, and July 16, 2026, and would leave approximately $54.8 million in outstanding principal amount of Notes. Omeros Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for inflammatory and inflammatory-related diseases.
